World's Best Scientists 2026 revealed!
Award Badge
Medicine
UK
2026

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 159 803 735 85 79 1148 125314

Johann S. de Bono publications per year

The chart shows the history of publications by Johann S. de Bono between 1999 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Johann S. de Bono published across 27 years, from 1999 to 2025, averaging 59 papers a year. Output peaked at 295 publications in 2023. 70 of the 1,592 publications appeared in the last two years.

No. of publications
50 100 150 200 250
Bar chart. Horizontal axis: year, 1999 to 2025. Vertical axis: number of publications, 0 to 295. Peak 295 publications in 2023. 1999: 1 publication 2000: 3 publications 2001: 4 publications 2002: 2 publications 2003: 4 publications 2004: 10 publications 2005: 14 publications 2006: 16 publications 2007: 37 publications 2008: 48 publications 2009: 52 publications 2010: 44 publications 2011: 78 publications 2012: 72 publications 2013: 80 publications 2014: 92 publications 2015: 95 publications 2016: 89 publications 2017: 103 publications 2018: 68 publications 2019: 55 publications 2020: 92 publications 2021: 90 publications 2022: 78 publications 2023: 295 publications 2024: 41 publications 2025: 29 publications
1999 2025

1,592 publications in total across all disciplines

View publications per year as a table
Johann S. de Bono: publications per year, 1999 to 2025
Year Publications
1999 1
2000 3
2001 4
2002 2
2003 4
2004 10
2005 14
2006 16
2007 37
2008 48
2009 52
2010 44
2011 78
2012 72
2013 80
2014 92
2015 95
2016 89
2017 103
2018 68
2019 55
2020 92
2021 90
2022 78
2023 295
2024 41
2025 29
Total 1,592
Download as CSV

Johann S. de Bono publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Johann S. de Bono sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 1,141–1,160 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 1,148 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51 1,148
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Johann S. de Bono D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Johann S. de Bono sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 158–159 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 159 D-Index — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74 159
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

Johann S. de Bono is affiliated with the Institute of Cancer Research in the United Kingdom and has contributed extensively to the field of cancer research, particularly in prostate cancer treatment and molecular oncology. Their research spans multiple domains within medicine and life sciences, showing a strong emphasis on integrating molecular biology with clinical applications.

The main fields of study in their work are Medicine and Biochemistry, Genetics and Molecular Biology. Within these, their subfields of focus include Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Cancer Research.

The main research topics covered in their publications reflect a concentration on several key areas:

  • Prostate Cancer Treatment and Research
  • Cancer Immunotherapy and Biomarkers
  • Radiopharmaceutical Chemistry and Applications
  • PARP inhibition in cancer therapy
  • Cancer, Lipids, and Metabolism
  • Cancer Genomics and Diagnostics
  • DNA Repair Mechanisms

Their recent and notable publications include:

  • "Pan-cancer analysis of whole genomes," 2020, Nature
  • "Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer," 2021, New England Journal of Medicine
  • "Olaparib for Metastatic Castration-Resistant Prostate Cancer," 2020, New England Journal of Medicine
  • "Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer," 2020, New England Journal of Medicine
  • "Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019," 2020, European Urology

Johann S. de Bono collaborates frequently with several researchers, reflecting an active role in academic networks. Frequent co-authors include Karim Fizazi, Bora Gürel, Adam Sharp, Suzanne Carreira, and Charles Schloss.

Their work appears regularly in a set of established publication venues, which include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • European Urology
  • Clinical Cancer Research

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

    Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

    Johann S. de Bono;Howard I. Scher;R. Bruce Montgomery;Christopher Parker

  • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

    Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud

Frequent Co-Authors

Gerhardt Attard
Gerhardt Attard University College London
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Fred Saad
Fred Saad University of Montreal
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Cora N. Sternberg
Cora N. Sternberg Cornell University
Arturo Molina
Arturo Molina Sutro Biopharma
Celestia S. Higano
Celestia S. Higano University of Washington
Eric J. Small
Eric J. Small University of California, San Francisco
Matthew R. Smith
Matthew R. Smith Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career isn’t limited to becoming a doctor. Online education offers several flexible and in-demand healthcare pathways. For those without a prior nursing background, direct entry msn programs allow non-nurses to transition quickly into advanced nursing roles, bypassing years of prerequisite study.

If you’re seeking a faster route to enter the nursing workforce, online adn programs for non nurses provide accessible entry-level options without requiring previous experience. Many institutions also cater to students who want to avoid standardized test barriers; for instance, you can find a nursing school that doesn't require teas or HESI exams.

An alternative pathway is administrative healthcare. Those interested in behind-the-scenes roles should consider accredited medical billing and coding schools with financial aid, where you can embark on a respected career supporting healthcare providers.

Overall, online healthcare degrees present diverse opportunities for both clinical and non-clinical roles, making it easier to find a pathway that matches your interests and background.

Best Scientists Citing Johann S. de Bono

Trending Scientists